123

Cell>Point Announces Agreement with the FDA on a Special Protocol Assessment for the Phase 3 Technetium-99m-EC-G Lung Cancer Imaging Trial

CENTENNIAL, Colo., March 8, 2012 – Cell>Point, L.L.C , announced today that it received a letter from the U.S. Food and Drug Administration (FDA) indicating that agreement has been reached pursuant to a Special Protocol Assessment regarding the design of its Phase 3 pivotal clinical study in lung cancer.

http://www.cellpointweb.com/spa-press-release-march-8-2012.pdf